Switching from Guselkumab to Tildrakizumab After Treatment Failure
Yes, switching from guselkumab to tildrakizumab is a reasonable and evidence-supported option for patients with plaque psoriasis who have failed to respond after one year of guselkumab treatment.
Rationale for Switching Between IL-23 Inhibitors
Both guselkumab and tildrakizumab are IL-23 p19 inhibitors with similar mechanisms of action—they both selectively block the p19 subunit of IL-23 1. However, primary failure to one biologic does not preclude successful response to another biologic, even within the same drug class 1. The 2019 AAD-NPF guidelines explicitly state that "if clinically needed, all other therapies for psoriasis, including other biologics, may be switched with a different biologic agent with the possibility of improved efficacy, safety, and/or tolerability" 1.
When to Consider the Switch
The guidelines recommend assessing definitive response to IL-23 inhibitors after 12 weeks of continuous therapy 1. Since your patient has been on guselkumab for one year without clinical improvement, this clearly represents primary treatment failure. At this point:
- Discontinue guselkumab and initiate tildrakizumab
- No washout period is required between IL-23 inhibitors given their similar safety profiles
- Consider whether loading doses need to be repeated based on disease severity and time elapsed (if more than 3-4 half-lives have passed since the last guselkumab dose, which has a half-life of 15-18 days) 1, 2
Tildrakizumab Dosing Protocol
Initiate tildrakizumab at the FDA-approved dosing regimen 1:
- 100 mg subcutaneous injection at Week 0
- 100 mg at Week 4
- 100 mg every 12 weeks thereafter
This is an in-office physician-administered injection per FDA labeling.
Expected Outcomes After Switching
Real-world evidence demonstrates that tildrakizumab is effective in patients who have failed previous biologic therapy:
- In a multicenter Italian study of 51 patients who had failed previous biologics, significant PASI reduction occurred by Week 12 (mean PASI decreased from 19.2 to 3.5), with further improvement at Week 48 (PASI 0.6) 3
- At Week 52, 87% achieved PASI 75,56.5% achieved PASI 90, and 32.6% achieved PASI 100 in real-world settings 4
- Long-term data through 148 weeks shows maintained efficacy with favorable safety profiles 5
Comparative Efficacy Considerations
While both drugs target the same pathway, network meta-analysis data suggests comparable efficacy between tildrakizumab, guselkumab, and risankizumab at Week 28 for PASI 75, PASI 90, and PGA 0/1 responses 6. However, individual patient response can vary due to:
- Differences in antibody structure (tildrakizumab is humanized IgG1κ vs. guselkumab's fully human IgG1λ)
- Potential development of anti-drug antibodies to guselkumab
- Individual immunologic variability
Important Caveats
The guidelines acknowledge that "not all switches may result in improvement" 1. However, given the patient's complete lack of response to guselkumab after one year, maintaining the current ineffective therapy offers no benefit while exposing the patient to continued disease burden and potential complications.
Alternative considerations if tildrakizumab also fails:
- Consider switching to a different mechanism of action (IL-17 inhibitors like secukinumab, ixekizumab, or brodalumab)
- Consider risankizumab (another IL-23 p19 inhibitor with potentially higher binding affinity)
- Evaluate for combination therapy with topical agents or methotrexate 1
Safety Profile
Tildrakizumab has demonstrated a favorable safety profile with low rates of discontinuation due to adverse events (1.2-1.7 per 100 patient-years) and low rates of serious infections, malignancies, and major adverse cardiovascular events 5. No new safety signals have emerged in real-world studies 3, 4, 7.